SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Paul Sieber discussing a post hoc analysis from the phase 3 EMBARK study assessing PSA dynamics. FDA approval of ...
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Jamie Thomas discussing results from the MAST trial assessing the validation of PAM50 for predicting progression in ...
BRAINERD — The public is welcome to a Sunday breakfast from 8 a.m. to noon March 16, at the Brainerd VFW, 309 S. Sixth St., ...
Trials have shown abiraterone can stop prostate cancer from spreading and it can extend the lives of those with the disease.
Community leaders are coming together to support colorectal and prostate cancer awareness with a little friendly competition.
In the study cohort, 2,310 patients died during a median follow-up of 6.3 years, and prostate cancer accounted for 454 (19.7% ...
Investigators found that some patients with high-risk nonmetastatic hormone-sensitive prostate cancer were understaged by ...
Scott Eggener, MD, gave a talk at the LUGPA annual meeting titled “Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments.” ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
These bills have been under the radar at the NC General Assembly — for now. What they are and their chances of becoming law.
Bowling for the Battle, a community-led event that works to raise money for prostate cancer research, will be returning Saturday in Austin.
Sexual function data support enzalutamide use in men with high-risk biochemically recurrent (BCR) prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results